Structural pathways for macromolecular and cellular transport all through the blood-brain barrier all through inflammatory circumstances. Analysis.
- This evaluation presents an abstract of the highlights of important concepts involving the anatomical routes for the transport of macromolecules and the transmigration of cellular elements all through the blood-brain barrier (BBB) all through irritation. The precise focus will embrace inflammatory leukocytes, neoplastic cells and pathogenic microorganisms along with explicit styles of viruses, micro organism and yeasts.
Anti-Tetanus Toxoid IgG (anti-TT IgG) ELISA Kit
- The experimental animal fashions launched proper right here have been employed effectively by the authors in a number of neutral experiments all through the earlier twenty-five years for investigations of pathologic alterations of the BBB after a variety of experimentally induced accidents and inflammatory circumstances in mammalian and non-mammalian animal species.
Human Junctional Adhesion Molecule 2/JAM-B AssayLite Antibody (PerCP Conjugate)
- The preliminary descriptions of endothelial cell (EC) vesicles or caveolae serving as mini-transporters of fluid substances mainly served as a springboard for lots of subsequent discoveries all through the earlier half century related to mechanisms of uptake of provides into ECs and whether or not or not or not pinocytosis is alleged to the transport of these provides all through EC obstacles beneath common physiologic circumstances and after tissue injury.
Tumor Necrosis Factor Receptor Superfamily Member 5 (CD40) Antibody
- Inside the mid-1970’s, the authors of this evaluation independently utilized morphologic strategies (transmission electron microscopy-TEM), along with the plant protein tracer horseradish peroxidase (HRP) to research macromolecular transport buildings that elevated after the thoughts and spinal twine had been subjected to a variety of accidents.
Survivin Antibody |
|||
2235-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: Survivin Antibody: Apoptosis, or programmed cell death, is related to many diseases, such as cancer. Apoptosis is triggered by a variety of stimuli including members in the TNF family and prevented by the inhibitor of apoptosis (IAP) proteins. IAP proteins form a conserved gene family that binds to and inhibits cell death proteases. A novel IAP protein was recently identified and designated survivin, apoptosis inhibitor 4 (API4), and TIAP. Survivin/TIAP interacted with the processed form of caspase-3 and inhibited its proteolytic activity. Survivin/TIAP is predominantly expressed in tissues of embryos, transformed cell lines, and many human cancers and lymphomas. |
Survivin Antibody |
|||
2237-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: Survivin Antibody: Apoptosis, or programmed cell death, is related to many diseases, such as cancer. Apoptosis is triggered by a variety of stimuli including members in the TNF family and prevented by the inhibitor of apoptosis (IAP) proteins. IAP proteins form a conserved gene family that binds to and inhibits cell death proteases. A novel IAP protein was recently identified and designated survivin, apoptosis inhibitor 4 (API4), and TIAP. Survivin/TIAP interacted with the processed form of caspase-3 and inhibited its proteolytic activity. Survivin/TIAP is predominantly expressed in tissues of embryos, transformed cell lines, and many human cancers and lymphomas. |
Survivin Antibody |
|||
2237-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: Survivin Antibody: Apoptosis, or programmed cell death, is related to many diseases, such as cancer. Apoptosis is triggered by a variety of stimuli including members in the TNF family and prevented by the inhibitor of apoptosis (IAP) proteins. IAP proteins form a conserved gene family that binds to and inhibits cell death proteases. A novel IAP protein was recently identified and designated survivin, apoptosis inhibitor 4 (API4), and TIAP. Survivin/TIAP interacted with the processed form of caspase-3 and inhibited its proteolytic activity. Survivin/TIAP is predominantly expressed in tissues of embryos, transformed cell lines, and many human cancers and lymphomas. |
Survivin Antibody |
|||
48663 | SAB | 100ul | EUR 499 |
Survivin Antibody |
|||
48663-100ul | SAB | 100ul | EUR 399.6 |
Survivin Antibody |
|||
48663-50ul | SAB | 50ul | EUR 286.8 |
Survivin Antibody |
|||
48710 | SAB | 100ul | EUR 499 |
Survivin Antibody |
|||
48710-100ul | SAB | 100ul | EUR 399.6 |
Survivin Antibody |
|||
48710-50ul | SAB | 50ul | EUR 286.8 |
Survivin antibody |
|||
70R-SR006 | Fitzgerald | 100 ug | EUR 321 |
Description: Affinity purified Rabbit polyclonal Survivin antibody |
Survivin antibody |
|||
70R-36165 | Fitzgerald | 100 ug | EUR 294 |
Description: Rabbit polyclonal Survivin antibody |
Survivin antibody |
|||
70R-36666 | Fitzgerald | 100 ug | EUR 294 |
Description: Rabbit Polyclonal Survivin antibody |
Survivin Antibody |
|||
E18-6017-1 | EnoGene | 50μg/50μl | EUR 145 |
Description: Available in various conjugation types. |
Survivin Antibody |
|||
E18-6017-2 | EnoGene | 100μg/100μl | EUR 225 |
Description: Available in various conjugation types. |
Survivin Antibody |
|||
E10-20176 | EnoGene | 100μg/100μl | EUR 225 |
Description: Available in various conjugation types. |
SURVIVIN antibody |
|||
70R-21713 | Fitzgerald | 50 ul | EUR 289 |
Description: Rabbit polyclonal SURVIVIN antibody |
Survivin antibody |
|||
70R-11659 | Fitzgerald | 100 ug | EUR 343 |
Description: Rabbit polyclonal Survivin antibody |
Survivin antibody |
|||
70R-11660 | Fitzgerald | 100 ug | EUR 375 |
Description: Rabbit polyclonal Survivin antibody |
Survivin antibody |
|||
70R-11668 | Fitzgerald | 100 ug | EUR 343 |
Description: Rabbit polyclonal Survivin antibody |
Survivin antibody |
|||
70R-14013 | Fitzgerald | 100 ug | EUR 519 |
Description: Affinity purified Rabbit polyclonal Survivin antibody |
Survivin Antibody |
|||
3160-100 | Biovision | each | EUR 379.2 |
Survivin Antibody |
|||
3160-30T | Biovision | each | EUR 175.2 |
Survivin Antibody |
|||
3161-100 | Biovision | each | EUR 405.6 |
Survivin Antibody |
|||
3170-100 | Biovision | each | EUR 379.2 |
Survivin Antibody |
|||
3170-30T | Biovision | each | EUR 175.2 |
Survivin Antibody |
|||
ABF6017 | Lifescience Market | 100 ug | EUR 525.6 |
Survivin Antibody |
|||
BF0201 | Affbiotech | 200ul | EUR 540 |
Survivin Antibody |
|||
BF0201-100ul | Affinity Biosciences | 100ul | EUR 210 |
Description: WB,ELISA |
Survivin Antibody |
|||
BF0201-200ul | Affinity Biosciences | 200ul | Ask for price |
Description: WB,ELISA |
Survivin Antibody |
|||
BF0201-50ul | Affinity Biosciences | 50ul | EUR 150 |
Description: WB,ELISA |
Survivin Antibody |
|||
B0578-100ul | Assay Biotech | 100μl | EUR 217 |
Description: Survivin Rabbit Polyclonal Antibody |
Survivin Antibody |
|||
B0578-50ul | Assay Biotech | 50μl | EUR 143.5 |
Description: Survivin Rabbit Polyclonal Antibody |
Survivin Antibody |
|||
B0579-100ul | Assay Biotech | 100μl | EUR 217 |
Description: Survivin Rabbit Polyclonal Antibody |
Survivin Antibody |
|||
B0579-50ul | Assay Biotech | 50μl | EUR 143.5 |
Description: Survivin Rabbit Polyclonal Antibody |
Survivin Antibody |
|||
AF7614 | Affbiotech | 200ul | EUR 540 |
Survivin Antibody |
|||
AF7614-100ul | Affinity Biosciences | 100ul | EUR 210 |
Description: WB,ELISA(peptide) |
Survivin Antibody |
|||
AF7614-200ul | Affinity Biosciences | 200ul | EUR 270 |
Description: WB,ELISA(peptide) |
Survivin Antibody |
|||
AF7614-50ul | Affinity Biosciences | 50ul | EUR 150 |
Description: WB,ELISA(peptide) |
Survivin Antibody |
|||
AF6017 | Affbiotech | 200ul | EUR 420 |
Survivin Antibody |
|||
AF6017-100ul | Affinity Biosciences | 100ul | EUR 168 |
Description: WB,IHC,IF/ICC,ELISA(peptide) |
Survivin Antibody |
|||
AF6017-200ul | Affinity Biosciences | 200ul | EUR 210 |
Description: WB,IHC,IF/ICC,ELISA(peptide) |
Survivin Antibody |
|||
DF6452 | Affbiotech | 200ul | EUR 420 |
Survivin Antibody |
|||
DF6452-100ul | Affinity Biosciences | 100ul | EUR 168 |
Description: WB,IHC,IF/ICC,ELISA(peptide) |
Survivin Antibody |
|||
DF6452-200ul | Affinity Biosciences | 200ul | EUR 210 |
Description: WB,IHC,IF/ICC,ELISA(peptide) |
Survivin Antibody |
|||
GWB-3DABA2 | GenWay Biotech | 0.1 mg | Ask for price |
Survivin, Antibody |
|||
GWB-4363F2 | GenWay Biotech | 1 ml | Ask for price |
Survivin, Antibody |
|||
GWB-53B086 | GenWay Biotech | 7 ml | Ask for price |
Survivin Antibody |
|||
E8RT1601 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
Survivin Antibody |
|||
E38PA6637 | EnoGene | 100ug/100ul | EUR 225 |
Survivin Antibody |
|||
E38PA9215 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
survivin Antibody |
|||
E300698 | EnoGene | 100ug/200ul | EUR 275 |
Description: Available in various conjugation types. |
Survivin Antibody |
|||
MBS150166-01mg | MyBiosource | 0.1mg | EUR 445 |
Survivin Antibody |
|||
MBS150166-5x01mg | MyBiosource | 5x0.1mg | EUR 1965 |
Survivin Antibody |
|||
MBS151070-01mg | MyBiosource | 0.1mg | EUR 445 |
Survivin Antibody |
|||
MBS151070-5x01mg | MyBiosource | 5x0.1mg | EUR 1965 |
Survivin Antibody |
|||
MBS151263-01mg | MyBiosource | 0.1mg | EUR 445 |
Survivin Antibody |
|||
MBS151263-5x01mg | MyBiosource | 5x0.1mg | EUR 1965 |
Survivin antibody |
|||
MBS532995-01mL | MyBiosource | 0.1mL | EUR 810 |
Survivin antibody |
|||
MBS532995-5x01mL | MyBiosource | 5x0.1mL | EUR 3505 |
Survivin antibody |
|||
MBS534573-01mg | MyBiosource | 0.1mg | EUR 555 |
Survivin antibody |
|||
MBS534573-5x01mg | MyBiosource | 5x0.1mg | EUR 2345 |
Survivin Antibody |
|||
MBS5311198-01mg | MyBiosource | 0.1mg | EUR 470 |
Survivin Antibody |
|||
MBS5311198-5x01mg | MyBiosource | 5x0.1mg | EUR 2080 |
Survivin Antibody |
|||
MBS5311199-01mg | MyBiosource | 0.1mg | EUR 505 |
Survivin Antibody |
|||
MBS5311199-5x01mg | MyBiosource | 5x0.1mg | EUR 2235 |
Survivin Antibody |
|||
MBS5311202-01mg | MyBiosource | 0.1mg | EUR 470 |
Survivin Antibody |
|||
MBS5311202-5x01mg | MyBiosource | 5x0.1mg | EUR 2080 |
Survivin Antibody |
|||
MBS5312786-01mg | MyBiosource | 0.1mg | EUR 975 |
Survivin Antibody |
|||
MBS5312786-5x01mg | MyBiosource | 5x0.1mg | EUR 4245 |
Survivin Antibody |
|||
MBS8512139-005mg | MyBiosource | 0.05mg | EUR 235 |
Survivin Antibody |
|||
MBS8512139-01mg | MyBiosource | 0.1mg | EUR 305 |
Survivin Antibody |
|||
MBS8512139-01mLAF405M | MyBiosource | 0.1mL(AF405M) | EUR 465 |
Survivin Antibody |
|||
MBS8512139-01mLAF546 | MyBiosource | 0.1mL(AF546) | EUR 465 |
Survivin Antibody |
|||
MBS8512139-01mLAF750 | MyBiosource | 0.1mL(AF750) | EUR 465 |
Survivin Antibody |
|||
MBS850379-01mg | MyBiosource | 0.1mg | EUR 305 |
Survivin Antibody |
|||
MBS850379-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
Survivin Antibody |
|||
MBS850379-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
Survivin Antibody |
|||
MBS850379-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
Survivin Antibody |
|||
MBS850379-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
survivin Antibody |
|||
MBS855192-01mg | MyBiosource | 0.1mg | EUR 345 |
Anti-Junctional Adhesion Molecule 1 Rabbit Monoclonal Antibody
- Based on morphologic proof from these analysis of BBB injury, the authors elaborated a singular EC system of modified caveolae that purportedly fused collectively forming transendothelial cell channels, and later comparable EC profiles outlined as vesiculo-canalicular or vesiculo-tubular buildings (VTS, Lossinsky, et al., 1999).
Human Anti-SSA/Ro Antibody (anti-Ro) ELISA Kit
- These EC buildings had been seen in affiliation with elevated BBB permeability of tracers along with exogenously injected HRP, normally excluded from the intercellular milieu of the CNS. Subsequent analysis of non-BBB-type tumor ECs determined that the EC VTS and totally different vesicular buildings had been outlined by others as vesiculo-vacuolar organelles (VVOs, Kohn et al., 1992; Dvorak et al., 1996). Collectively, these buildings appear to indicate a form of anatomical gateway to the CNS potential serving as conduits.
B-Lymphocyte Cell Adhesion Molecule (BL-CAM) Antibody
- Nonetheless, these CNS conduits develop to be patent solely in damaged ECs for the passage of macromolecules, and purportedly for inflammatory and neoplastic cells as successfully (Lossinsky et al., 1999). On this evaluation, we focus consideration on the similarities and variations between caveolae, fused racemic vesicular bundles, endothelial tubules and channels (VTS and the VVOs) which may be manifest in common, non-BBB-type blood vessels, and throughout the BBB after injury.
- This evaluation will present proof that the sooner analysis by the authors and totally different researchers established a framework for subsequent transmission (TEM), scanning (SEM) and high-voltage electron microscopic (HVEM) investigations concerning ultrastructural, ultracytochemical and immunoultra-structural alterations of the cerebral ECs and the mechanisms of the BBB transport that occurs after CNS injury.
- This evaluation won’t be supposed to include all the numerous observations that’s maybe included in a fundamental historic overview of the occasion of the EC channel hypothesis, nonetheless it’s going to speak about various of the foremost contributions. We now have tried to present a number of of the structural proof that helps our early contributions and other people made by totally different investigators by highlighting important choices of these EC buildings which may be manifest throughout the injured BBB. We now have centered on presently established concepts and guidelines related to mechanisms for the transendothelial transport of macromolecules after CNS injury and likewise present a vital appraisal of some of this literature.
Recombinant Human Intercellular Adhesion Molecule-1
- Lastly, we describe newer concepts of transBBB avenues for viruses, along with HIV-1, bacterial and mycotic organisms, along with inflammatory and neoplastic cell adhesion and migration all through the injured mammalian BBB. Data from analysis of EC-related adhesion molecules, every from the literature and from the creator’s experimental outcomes and observations made in several laboratories, along with from non-public communications underscore the importance of the adhesion molecules in
Tivantinib |
|||
B1546-25 | Biovision | each | EUR 496.8 |
Tivantinib |
|||
B1546-5 | Biovision | each | EUR 170.4 |
Tivantinib |
|||
HY-50686 | MedChemExpress | 5mg | EUR 1233.79 |
Description: Tivantinib is a highly selective c-Met tyrosine kinase inhibitor with a Ki of 355 nM. |
Tivantinib |
|||
MBS3606505-100mg | MyBiosource | 100mg | EUR 480 |
Tivantinib |
|||
MBS3606505-10mg | MyBiosource | 10mg | EUR 220 |
Tivantinib |
|||
MBS3606505-25mg | MyBiosource | 25mg | EUR 275 |
Tivantinib |
|||
MBS3606505-50mg | MyBiosource | 50mg | EUR 345 |
Tivantinib |
|||
MBS3606505-5mg | MyBiosource | 5mg | EUR 200 |
Tivantinib |
|||
T447200 | Toronto Research Chemicals | 5mg | EUR 58 |
Description: 905854-02-6 |
Tivantinib |
|||
T6117-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: Tivantinib |
Tivantinib |
|||
T6117-1g | TargetMol Chemicals | 1g | Ask for price |
Description: Tivantinib |
Tivantinib |
|||
T6117-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: Tivantinib |
Tivantinib |
|||
T6117-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: Tivantinib |
Tivantinib |
|||
T6117-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: Tivantinib |
(Rac)-Tivantinib |
|||
HY-76688 | MedChemExpress | 10 mg | EUR 974.04 |
Description: (Rac)-Tivantinib is the inactive isomer of Tivantinib (HY-50686), and can be used as an experimental control. Tivantinib is a highly selective c-Met tyrosine kinase inhibitor with a Ki of 355 nM. |
(rel)-Tivantinib |
|||
HY-77493 | MedChemExpress | 100 mg | EUR 238.1 |
Description: (rel)-Tivantinib is a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET. (rel)-Tivantinib has two novel targets, GSK3α and GSK3β, which play an important role in the cellular mechanism of non-small cell lung cancer (NSCLC)[1]. |
ARQ 197, Tivantinib |
|||
MBS132509-100mg | MyBiosource | 100mg | EUR 1065 |
ARQ 197, Tivantinib |
|||
MBS132509-500mg | MyBiosource | 500mg | EUR 2775 |
(3S,4S)-Tivantinib |
|||
HY-50687 | MedChemExpress | 100 mg | EUR 411.26 |
Description: (3S,4S)-Tivantinib is a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET. (3S,4S)-Tivantinib has two novel targets, GSK3α and GSK3β, which play an important role in the cellular mechanism of non-small cell lung cancer (NSCLC)[1]. |
Tivantinib (ARQ 197) |
|||
A8325-100 | ApexBio | 100 mg | EUR 304 |
Description: Tyrosine Kinase|c-MET |
Tivantinib (ARQ 197) |
|||
A8325-20 | ApexBio | 20 mg | EUR 96 |
Description: Tyrosine Kinase|c-MET |
Tivantinib (ARQ 197) |
|||
A8325-5 | ApexBio | 5 mg | EUR 44 |
Description: Tyrosine Kinase|c-MET |
Tivantinib (ARQ 197) |
|||
A8325-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 52 |
Description: Tyrosine Kinase|c-MET |
Tivantinib (ARQ 197) |
|||
A8325-S | ApexBio | Evaluation Sample | EUR 24 |
Description: Tyrosine Kinase|c-MET |
Tivantinib (ARQ 197) |
|||
MBS578686-100mg | MyBiosource | 100mg | EUR 420 |
Tivantinib (ARQ 197) |
|||
MBS578686-10mg | MyBiosource | 10mg | EUR 160 |
Tivantinib (ARQ 197) |
|||
MBS578686-25mg | MyBiosource | 25mg | EUR 215 |
Tivantinib (ARQ 197) |
|||
MBS578686-50mg | MyBiosource | 50mg | EUR 280 |
Tivantinib (ARQ 197) |
|||
MBS578686-5mg | MyBiosource | 5mg | EUR 135 |
Tivanisiran |
|||
HY-132596 | MedChemExpress | 10 mg | EUR 779.23 |
Description: Tivanisiran (SYL1001) is a siRNA used for the study of dry eye disease. Tivanisiran was designed to silence transient receptor potential vanilloid 1 (TRPV1) mRNA[1]. |
Tivanisiran |
|||
MBS5799799-10mg | MyBiosource | 10(mg | EUR 1350 |
Tivanisiran |
|||
MBS5799799-5x10mg | MyBiosource | 5x10mg | EUR 5915 |
Tivanisiran |
|||
T39293-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: Tivanisiran |
Tivanisiran |
|||
T39293-1g | TargetMol Chemicals | 1g | Ask for price |
Description: Tivanisiran |
Tivanisiran |
|||
T39293-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: Tivanisiran |
Tivanisiran |
|||
T39293-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: Tivanisiran |
Tivanisiran |
|||
T39293-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: Tivanisiran |
VAMP7/TI-VAMP ELISA KIT|Human |
|||
EF004168 | Lifescience Market | 96 Tests | EUR 826.8 |
anti- VAMP7/TI-VAMP antibody |
|||
FNab09364 | FN Test | 100µg | EUR 658.5 |
Description: Antibody raised against VAMP7/TI-VAMP |
Anti-VAMP7/TI-VAMP antibody |
|||
PAab09364 | Lifescience Market | 100 ug | EUR 463.2 |
Tivozanib |
|||
200955 | MedKoo Biosciences | 5.0mg | EUR 90 |
Tivozanib |
|||
B1545-25 | Biovision | each | EUR 705.6 |
Tivozanib |
|||
B1545-5 | Biovision | each | EUR 222 |
Tivozanib |
|||
GP9162 | Glentham Life Sciences | 1mg | EUR 367.64 |
Tivozanib |
|||
GP9162-1 | Glentham Life Sciences | 1 | EUR 171.5 |
Tivozanib |
|||
GP9162-10 | Glentham Life Sciences | 10 | EUR 343.5 |
Tivozanib |
|||
GP9162-5 | Glentham Life Sciences | 5 | EUR 254 |
Tivozanib |
|||
HY-10977 | MedChemExpress | 200mg | EUR 343.08 |
Description: Tivozanib (AV-951; KRN951) is a selective and orally active VEGFR tyrosine kinase inhibitor with IC50 of 0.21, 0.16, 0.24 nM for VEGFR-1, VEGFR-2, VEGFR-3, respectively. Tivozanib inhibits angiogenesis and vascular permeability in tumor tissues and shows antitumor activity. Tivozanib has the potential for the research of metastatic renal cell carcinoma (RCC) [1][2][3]. |
Tivozanib |
|||
MBS3604577-10mg | MyBiosource | 10mg | EUR 240 |
Tivozanib |
|||
MBS3604577-25mg | MyBiosource | 25mg | EUR 310 |
Tivozanib |
|||
MBS3604577-2mg | MyBiosource | 2mg | EUR 200 |
Tivozanib |
|||
MBS3604577-50mg | MyBiosource | 50mg | EUR 365 |
Tivozanib |
|||
MBS3604577-5mg | MyBiosource | 5mg | EUR 220 |
Tivozanib |
|||
T447205 | Toronto Research Chemicals | 10mg | EUR 460 |
Description: 475108-18-0 |
Tivozanib |
|||
T2456-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: Tivozanib |
Tivozanib |
|||
T2456-1g | TargetMol Chemicals | 1g | Ask for price |
Description: Tivozanib |
Tivozanib |
|||
T2456-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: Tivozanib |
Tivozanib |
|||
T2456-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: Tivozanib |
Tivozanib |
|||
T2456-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: Tivozanib |
Tivirapine |
|||
MBS5778645-5mg | MyBiosource | 5(mg | EUR 915 |
Tivirapine |
|||
MBS5778645-5x5mg | MyBiosource | 5x5(mg | EUR 3970 |
Tivirapine |
|||
T28981-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: Tivirapine |
Tivirapine |
|||
T28981-1g | TargetMol Chemicals | 1g | Ask for price |
Description: Tivirapine |
Tivirapine |
|||
T28981-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: Tivirapine |
Tivirapine |
|||
T28981-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: Tivirapine |
Tivirapine |
|||
T28981-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: Tivirapine |
Tivozanib (AV-951) |
|||
A2251-10 | ApexBio | 10 mg | EUR 68 |
Description: Tyrosine Kinase|VEGFR |
Tivozanib (AV-951) |
|||
A2251-100 | ApexBio | 100 mg | EUR 240 |
Description: Tyrosine Kinase|VEGFR |
Tivozanib (AV-951) |
|||
A2251-25 | ApexBio | 25 mg | EUR 96 |
Description: Tyrosine Kinase|VEGFR |
Tivozanib (AV-951) |
|||
A2251-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 75.2 |
Description: Tyrosine Kinase|VEGFR |